ALCAM and pachyonychia congenita: In addition, Sanders et al45 determined the serum ALCAM levels in samples of 239 PC patients and found higher ALCAM levels to be associated with higher Gleason‐score, T‐stage and PSA levels suggesting an association between increasing serum ALCAM concentrations during prostate cancer progression.